Fresh Tracks Therapeutics, Inc.

$0.94-0.53%($-0.01)
TickerSpark Score
76/100
Solid
80
Valuation
40
Profitability
95
Growth
84
Health
80
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FRTX research report →

52-Week Range90% of range
Low $0.03
Current $0.94
High $1.03

Companywww.frtx.com

Fresh Tracks Therapeutics, Inc. , a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors.

CEO
Albert Nicholas Marchio II
IPO
1993
Employees
4
HQ
Boulder, CO, US

Price Chart

+3.64% · this period
$1.00$0.82$0.65Feb 28Aug 28Feb 28

Valuation

Market Cap
$5.59M
P/E
-0.97
P/S
0.70
P/B
0.56
EV/EBITDA
0.94
Div Yield
0.00%

Profitability

Gross Margin
100.00%
Op Margin
-79.44%
Net Margin
-71.12%
ROE
-66.50%
ROIC
-64.05%

Growth & Income

Revenue
$8.01M · 15.31%
Net Income
$-5,694,000 · 72.44%
EPS
$-0.96 · 86.96%
Op Income
$-6,360,000
FCF YoY
77.59%

Performance & Tape

52W High
$1.03
52W Low
$0.03
50D MA
$0.81
200D MA
$0.81
Beta
1.17
Avg Volume
2.67K

Get TickerSpark's AI analysis on FRTX

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Jun 10, 24Exploration Capital, LLCbuy86,185
Jun 7, 24Exploration Capital, LLCbuy319,315
May 31, 24Exploration Capital, LLCbuy516
May 30, 24Exploration Capital, LLCbuy9,838
May 29, 24Exploration Capital, LLCbuy80
May 23, 24Exploration Capital, LLCbuy15,627
May 22, 24Exploration Capital, LLCbuy383
May 21, 24Exploration Capital, LLCbuy6,879
May 20, 24Exploration Capital, LLCbuy797
May 16, 24Exploration Capital, LLCbuy73,768

Our FRTX Coverage

We haven't published any research on FRTX yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate FRTX Report →

Similar Companies